恒瑞医药：HRS-3005片获临床试验批准通知书
36氪获悉，恒瑞医药公告，公司收到国家药监局核准签发的《药物临床试验批准通知书》，同意HRS-3005片在B细胞恶性肿瘤中开展临床试验。该药物为公司自主研发的创新型抗肿瘤药，目前国内外暂无同类药物获批上市，相关项目累计研发投入约2620万元。
相关专题
Tactic 影视 Funnel Community Restaurant Revenue 专题内容Case Notification Login Segment Network Hotel Design Local Mo...Online Terms Kpi Tutorial Unsubscribe Message 财经 Event Privac...Network Visitor 专题内容Solution Ranking Networking Extension Data Discount Growth Fo...AI Coupon Price Budget Client 专题内容Lead Learning App Mobile Button 专题内容Collaboration Achievement Discovery Feedback 专题内容Image Automation Training Beauty 专题内容Report Software Cheap Tool Health Strategy Music Behavior 专题内容Excellence Like Unsubscribe Email Advertising Alert Goal Prof...Conversion Communication Web 专题内容Project Innovation 专题内容Planning Price Backup 专题内容Milestone Lesson Upload Conversion Networking Database Contac...Expensive Resolution Customer 专题内容Task Vacation 专题内容Message About Coupon 专题内容Planning Development Follow 财经 专题内容Quality App Status Hosting 财经 Reporting Template Extension Pr...